|
Dr. Russell Medford has served as a member of AtheroGenics’ board of directors since the Company’s inception in 1993. Dr. Medford has been the President and Chief Executive Officer since 1995 after serving as Executive Vice President from 1993 to 1995.
Dr. Medford is a director of Inhibitex, Inc. (Nasdaq: INHX). He is an inaugural Fellow of the Council on Basic Cardiovascular Sciences of the American Heart Association and a past member of the Advisory Council of the National Heart, Lung and Blood Institute. Dr. Medford serves on the Biotechnology Industry Organization's (BIO) Board of Directors and the Emerging Companies Section Governing Body. He serves as Chairman of the Georgia BioMedical Partnership and is a member of House Georgia Bioeconomic Development Study Committee and the Southeast BIO (SEBIO) Board of Directors.
Dr. Medford was an Associate Professor of Medicine and Director of Molecular Cardiology at the Emory University School of Medicine, and currently holds the appointment of Adjunct Clinical Professor of Medicine. Dr. Medford is a molecular cardiologist whose research has focused on the molecular basis of cardiovascular disease. He has published widely in the field of molecular cardiology and holds 16 U.S. patents. Dr. Medford received a B.A. from Cornell University, and an M.D. with Distinction and a Ph.D. in molecular and cell biology from the Albert Einstein College of Medicine. Dr. Medford completed his residency in internal medicine at the Beth Israel Hospital and served as a fellow in cardiology at the Brigham and Women's Hospital and Harvard Medical School, where he also served on the faculty of Medicine. | 